Payment overview · 2025
General Payments
$1,574.11
80 reported records · 18 companies
Healthcare provider profile · identity verified
Eric Lu, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · ANAHEIM, CA · NPI 1841498565
Verified facts
What the public records show
CMS Open Payments records show Eric Lu, PA-C received $1,574.11 in general payments during 2025 across 80 reported records.
Amgen Inc. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Jardiance, Kerendia, Ozempic, Shingrix, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $320.41 | 20.4% | 24 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $201.64 | 12.8% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $158.38 | 10.1% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $146.79 | 9.3% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $139.13 | 8.8% | 7 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $124.61 | 7.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $113.60 | 7.2% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $101.33 | 6.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $75.54 | 4.8% | 3 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $32.95 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $32.50 | 2.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.61 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.00 | 1.3% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $19.27 | 1.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.83 | 1.1% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $16.80 | 1.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.26 | 1.0% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $14.46 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,562.55 | 79 |
| Education | $11.56 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $320.41 | 24 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $282.23 | 21 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $159.75 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $124.61 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $99.96 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $95.56 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $95.56 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $95.56 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $89.60 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $83.36 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $81.53 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $71.24 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $65.26 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $61.34 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.89 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $43.57 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $42.91 | 2 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $32.95 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $32.95 | 1 | 2025 |
Source payment records
|
|||||
| ID NOW INSTRUMENT Normalized: id now instrument |
Device | Abbott Laboratories | $32.50 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $29.77 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.50 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $14.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 63 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 217 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 99 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 47 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 28 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
217 | 69 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
47 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
63 | 63 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
28 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
60 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 582 | 224 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 427 | 136 |
| Omeprazole | Omeprazole | 300 | 127 |
| Gabapentin | Gabapentin | 299 | 110 |
| Losartan Potassium | Losartan Potassium | 296 | 125 |
| Fluticasone Propionate | Fluticasone Propionate | 282 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 254 | 113 |
| Naproxen | Naproxen | 252 | 86 |
| Metformin Hcl | Metformin Hcl | 239 | 105 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 231 | 48 |
| Baclofen | Baclofen | 227 | 80 |
| Farxiga | Dapagliflozin Propanediol | 217 | 69 |
| Alendronate Sodium | Alendronate Sodium | 191 | 72 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 182 | 49 |
| Famotidine | Famotidine | 167 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 64 |
| Meclizine Hcl | Meclizine Hcl | 153 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 61 |
| Lisinopril | Lisinopril | 123 | 55 |
| Montelukast Sodium | Montelukast Sodium | 106 | 40 |
| Allopurinol | Allopurinol | 103 | 39 |
| Jardiance | Empagliflozin | 99 | 29 |
| Ibuprofen | Ibuprofen | 90 | 58 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 87 | 34 |
| Atenolol | Atenolol | 80 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 73 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 20 |
| Sucralfate | Sucralfate | 72 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 68 | 27 |
| Mometasone Furoate | Mometasone Furoate | 67 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 23 |
| Clobetasol Propionate | Clobetasol Propionate | 64 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 63 | 63 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 63 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 50 |
| Celecoxib | Celecoxib | 61 | 24 |
| Rybelsus | Semaglutide | 60 | 16 |
| Trulicity | Dulaglutide | 58 | 11 |
| Simvastatin | Simvastatin | 55 | 28 |
| Tramadol Hcl | Tramadol Hcl | 55 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 21 |
| Vascepa | Icosapent Ethyl | 52 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | 20 |
| Procto-Med Hc | Hydrocortisone | 50 | 13 |
| Hydrocortisone | Hydrocortisone | 49 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 48 | 38 |
| Furosemide | Furosemide | 48 | 20 |
| Januvia | Sitagliptin Phosphate | 48 | suppressed |
| Kerendia | Finerenone | 47 | 12 |
| Trazodone Hcl | Trazodone Hcl | 46 | 19 |
| Azelastine Hcl | Azelastine Hcl | 44 | 11 |
| Finasteride | Finasteride | 44 | 19 |
| Mupirocin | Mupirocin | 44 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 14 |
| Meloxicam | Meloxicam | 42 | 19 |
| Amoxicillin | Amoxicillin | 40 | 28 |
| Azithromycin | Azithromycin | 40 | 38 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 40 | 16 |
| Ozempic | Semaglutide | 40 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 29 |
| Sertraline Hcl | Sertraline Hcl | 39 | 16 |
| Carvedilol | Carvedilol | 37 | 14 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 36 | 36 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 28 |
| Donepezil Hcl | Donepezil Hcl | 32 | 14 |
| Eliquis | Apixaban | 32 | 11 |
| Myrbetriq | Mirabegron | 31 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 29 | 14 |
| Levofloxacin | Levofloxacin | 29 | 26 |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 28 | 23 |
| Clonidine Hcl | Clonidine Hcl | 26 | 15 |
| Lovastatin | Lovastatin | 26 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Comfort Ez Pro Safety Pen Ndl | Pen Needle, Diabetic, Safety | 25 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | 11 |
| Benazepril Hcl | Benazepril Hcl | 23 | 11 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | 12 |
| Glimepiride | Glimepiride | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | 11 |
| M-M-R Ii Vaccine | Measles,mumps,rubella Vacc/Pf | 23 | 23 |
| Nitroglycerin | Nitroglycerin | 23 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 19 |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | 11 |
| Glipizide | Glipizide | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Prednisone | Prednisone | 17 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 12 |
| Fluocinonide | Fluocinonide | 15 | suppressed |
| Ofloxacin | Ofloxacin | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,574.11 · 80 records | Amgen Inc. | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, FARXIGA, Fluad, Flucelvax, GARDASIL 9, GVOKE HYPOPEN, ID NOW INSTRUMENT, JARDIANCE, Kerendia, MOUNJARO, NUCALA, NURTEC ODT, Natroba, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, SHINGRIX, Spinosad, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VAXNEUVANCE, VOQUEZNA, Wegovy, Xhance, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error